Skip to search formSkip to main contentSkip to account menu

matuzumab

Known as: humanized anti-EGFR monoclonal antibody 
A humanized monoclonal antibody with antineoplastic activity. Matuzumab binds the epidermal growth factor receptor (EGFR) with high affinity… 
National Institutes of Health

Related topics

Related topics

5 relations

Broader (1)

Antibodies, Monoclonal, Humanized

Narrower (1)

EMD 72000
NCIt Antineoplastic Agent Terminologyantigen bindingcapecitabine/cisplatin/epirubicin/matuzumab

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2013
Review
2013
Molecular Targeted Agents for Gastric Cancer: A Step Forward Towards Personalized Therapy
Gastric cancer (GC) represents a major cancer burden worldwide, and remains the second leading cause of cancer-related death. Due… 
Review
2011
Review
2011
Monoclonal antibodies against EGFR in non-small cell lung cancer.
Review
2010
Review
2010
Pemetrexed with or without Matuzumab as Second-Line Treatment for Patients with Stage IIIB/IV Non-small Cell Lung Cancer
Introduction: This randomized phase II study investigated pemetrexed in combination with the epidermal growth factor receptor… 
2010
2010
Peptide mimotopes recognized by antibodies cetuximab and matuzumab induce a functionally equivalent anti-EGFR immune response
Aberrant activation of the epidermal growth factor receptor (EGFR) has been found in human cancers of various origins, and has… 
Highly Cited
2009
Highly Cited
2009
Interaction between fatty acid synthase- and ErbB-systems in ovarian cancer cells.
Review
2007
Review
2007
EGFR targeting of solid tumors.
BACKGROUND Recent clinical trials suggest that epidermal growth factor receptor (EGFR)-targeted agents could benefit many… 
Review
2007
Review
2007
Antibodies to the Epidermal Growth Factor Receptor in Non–Small Cell Lung Cancer: Current Status of Matuzumab and Panitumumab
Matuzumab and panitumumab are antibodies against the epidermal growth factor receptor (EGFR) that are being evaluated in several… 
Highly Cited
2006
Highly Cited
2006
A phase I study of the humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with paclitaxel in patients with EGFR-positive advanced non…
BACKGROUND Epidermal growth factor receptor (EGFR) is overexpressed in 80%-90% of non-small-cell lung cancer (NSCLC). Matuzumab… 
Review
2005
Review
2005
Novel targeted therapies in the treatment of gastric and esophageal cancer.
Esophageal cancer (EC) and gastric cancer (GC) constitute a major cause of cancer deaths worldwide. Recent improvements in both… 
2004
2004
Technology evaluation: Matuzumab, Merck KGaA.
  • Tracy Kim
  • Current opinion in molecular therapeutics (Print)
  • 2004
  • Corpus ID: 42460815
Merck KGaA is developing matuzumab, a fully humanized epidermal growth factor receptor (EGFR)-specific monoclonal antibody, as a… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)